Tenon Medical, Inc. Sets Date for Fourth Quarter and Full Year 2025 Earnings, Reaffirms Expected Revenues
Tenon Medical (NASDAQ:TNON) said it will report fourth quarter and full year 2025 results after market close on March 19, 2026 and host a conference call the same day at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tenon Medical (NASDAQ:TNON) said it will report fourth quarter and full year 2025 results after market close on March 19, 2026 and host a conference call the same day at 4:30 p.m. ET. The company provided revenue ranges: Q4 2025 $1.45–$1.48M (~90% YoY) and FY2025 $3.91–$3.94M (~20% YoY). Dial‑in, international numbers, webcast details, and replay access through April 2, 2026 were provided, with telephone replay access code 13758268.
Positive
- Q4 2025 revenue range of $1.45–$1.48M, ~90% year‑over‑year growth
- Full‑year 2025 revenue range of $3.91–$3.94M, ~20% year‑over‑year growth
Negative
- Full‑year revenue remains under $4.0M for 2025, indicating a small absolute revenue base
Details
News Market Reaction – TNON
On Feb 5, the day this news came out, TNON closed 2.26% below the previous close.
Data tracked by StockTitan Argus for the Feb 5 session.
Key Figures
- Q4 2025 revenue guidance
- $1.45–$1.48M
- Pre-announced range for Q4 2025 revenue
- Q4 YoY growth
- 90% year over year
- Growth rate implied for Q4 2025 revenue
- Full-year 2025 revenue
- $3.91–$3.94M
- Pre-announced range for full-year 2025 revenue
- Full-year YoY growth
- 20% year over year
- Growth rate implied for 2025 revenue
- Earnings call time
- 4:30 p.m. Eastern
- Scheduled March 19, 2026 conference call start time
Historical Context
-
Preliminary Q4 and full-year 2025 revenues with strong YoY growth update.
-
Initial cases and supporting data for new SImmetry+ SI Joint Fusion System.
-
Closing of $2.85M at-the-market PIPE with shares and warrants issued.
-
Q3 2025 financials with higher revenue, improved margin, and net loss.
-
Pricing details for PIPE offering with shares and warrants to raise funds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sacro-pelvic disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fourth Quarter 2025 Revenue of
Full Year 2025 Revenue of
LOS GATOS, CA / ACCESS Newswire / February 5, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company redefining care for patients suffering from sacro-pelvic disorders, today announced plans to release financial results for the fourth quarter and full year 2025 ended December 31, 2025 after market close on Thursday, March 19, 2026. The Company will also hold a conference call on the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with its covering analysts.
Date: | Thursday, March 19, 2026 |
Time: | 4:30 p.m. Eastern time |
Dial-in: | 1-877-407-0792 |
International Dial-in: | 1-201-689-8263 |
Webcast: |
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
An audio playback of the call will be available through April 2, 2026, on Tenon's Investor Relations website at http://ir.tenonmed.com/ or via telephone replay by dialing 1-844-512-2921 (USA) or 1-412-317-6671 (International). The access code will be 13758268.
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022, Tenon is focused on three commercial opportunities with its System in the SI Joint market which include: 1) Primary SI Joint procedures, 2) Revision procedures of failed SI Joint implants and 3) Augmenting spinal fusion. For more information, please visit www.tenonmed.com.
The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.
Investor Contact
Shannon Devine
MZ North America
203-741-8811
tenon@mzgroup.us
SOURCE: Tenon Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.